BEDROCK Act
- Sponsor
- Rep. Latta, Robert E. [R-OH-5]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Aug 27, 2026
Bottom line
The BEDROCK Act aims to bolster the U.S. biomanufacturing sector by identifying and addressing supply chain weaknesses, streamlining federal regulatory pathways, and promoting domestic competitiveness.
What it actually does
This bill directs the Secretary of Commerce to establish a program to promote U.S. biomanufacturing competitiveness. It mandates the designation of a senior official, biennial assessments of biomanufacturing supply chain vulnerabilities, and the identification of industry best practices. Additionally, it requires a report mapping federal commercialization processes for biomanufactured products and mandates the FDA and EPA to designate points of contact for industry inquiries.
Proponents argue
Supporters argue that this bill is crucial for enhancing national security by reducing reliance on foreign adversaries for critical biomanufacturing inputs. They contend it will foster domestic innovation, create jobs, and ensure the United States remains a global leader in the vital and rapidly growing biomanufacturing industry by addressing existing market and regulatory barriers.
Opponents contend
Critics might argue that the bill creates new bureaucratic layers within the Department of Commerce, potentially duplicating efforts already underway in other federal agencies without a clear demonstration of added value. Some may also express concern that the focus on 'foreign adversaries' could lead to protectionist measures that hinder global scientific collaboration and market efficiency, ultimately raising costs for consumers.
The bill is concise and clearly structured, allowing an informed reader to understand its provisions and implications within a reasonable timeframe.
Section 2(a)-(b)
Establishment of Biomanufacturing Competitiveness Program
This provision mandates the Secretary of Commerce to appoint a senior official to spearhead efforts in promoting U.S. biomanufacturing competitiveness. This official will identify challenges like supply chain vulnerabilities, market barriers, and unclear federal processes, while also highlighting opportunities for domestic production growth. They will also create a public online resource for relevant federal information and act as a contact point for non-federal entities seeking publicly available information.
Supporters argue
Supporters argue this provision centralizes and focuses federal efforts on biomanufacturing, providing a clear point of contact and a strategic framework essential for national economic and security interests in this critical industry.
Critics contend
Critics might contend that creating a new senior official and associated activities could lead to bureaucratic bloat and potential overlap with existing initiatives in other agencies, without guaranteeing tangible improvements or efficient resource allocation.
Tradeoffs
This provision balances the need for focused leadership in a strategic industry with the risk of creating redundant bureaucratic structures across the federal government.
Section 2(c)
Biennial Biomanufacturing Supply Chain Assessment and Action Plan
Every two years, the Secretary of Commerce must conduct a comprehensive assessment of the current and foreseeable future availability of critical biomanufacturing inputs and domestic production capacity. This includes evaluating reliance on foreign adversaries, identifying supply chain vulnerabilities, and estimating the lead times and economic barriers to reducing such dependencies. Based on these findings, a prioritized action plan will be developed to address identified risks and barriers.
Section 2(d)
Publicly Available Voluntary Industry Practices
This section requires the Secretary of Commerce to identify and make publicly available existing, industry-led best practices for various aspects of biomanufacturing. These practices cover commercialization, production readiness, reliability, supply chain risk management, information sharing, intellectual property protection, participation of small and medium-sized businesses, and the use of digital tools. The goal is to promote transparency and efficiency across the industry through voluntary adoption.
Section 2(e)
Streamlining Federal Commercialization Pathways
The bill mandates a report that identifies and maps all federal processes applicable to the commercialization of biomanufactured products and their critical inputs, highlighting any overlaps, gaps, ambiguities, and opportunities for improvement. Furthermore, it requires the Food and Drug Administration (FDA) and the Environmental Protection Agency (EPA) to designate specific points of contact to assist non-federal entities in navigating their respective regulatory processes, aiming to improve clarity and predictability for businesses.
Establishes protections for sensitive nonpublic information (trade secrets, confidential business information, sensitive supply-chain vulnerability information) voluntarily submitted by non-Federal entities to the Secretary of Commerce under this Act, exempting it from public disclosure, including under the Freedom of Information Act (FOIA). It also creates a process for entities to identify such information and for the Secretary to make a determination.
Section 2(f)
Why it matters:This is standard legislative practice to ensure that private sector entities feel secure sharing sensitive data with the government for policy purposes without fear of competitive disadvantage or public exposure. It is necessary to facilitate candid information exchange.
Case for: Supporters argue this provision is essential to encourage private sector participation and candid sharing of information, which is critical for the Secretary to accurately assess supply chain vulnerabilities and market barriers. Without it, companies would be hesitant to provide the necessary data.
Case against: Critics might contend that broad exemptions from public disclosure, even for sensitive information, can reduce transparency and public oversight of government activities, potentially shielding information that could be relevant for public interest or accountability.
Estimated impact: Enables greater data collection and cooperation from the private sector, which is crucial for the bill's effectiveness, but reduces public access to certain data that could otherwise be subject to FOIA requests.
Specifies that the core requirements of the Act, including the designation of a senior official, mandated activities, biennial assessments, identification of voluntary practices, and the commercialization pathway map and reports, will terminate five years after the date of enactment.
Section 2(h)
Why it matters:Sunset clauses are often included to ensure that programs are reviewed and reauthorized by Congress after a set period, preventing indefinite bureaucratic expansion. It can also serve as a compromise to gain broader support for a new initiative by limiting its initial scope and fiscal commitment.
Case for: Proponents would argue that a sunset clause ensures accountability and allows Congress to review the effectiveness of the program after five years, preventing it from becoming a permanent fixture if it doesn't deliver results or if circumstances change.
Case against: Opponents might contend that a five-year termination period is too short for a complex initiative like strengthening biomanufacturing supply chains, potentially leading to a lack of long-term strategic planning and investment, or creating uncertainty for industry participants.
Estimated impact: Limits the duration of the bill's core mandates to five years, requiring future legislative action for continuation. This impacts the long-term stability and planning for the biomanufacturing program.